Cargando...
Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestation
BACKGROUND: To evaluate the efficacy and safety of telbivudine in chronic hepatitis B women during the second and third trimesters of pregnancy. METHODS: The week 12–34 of pregnant women were screened in this prospective non-intervention study, with HBV DNA > 10(6) IU/mL and alanine aminotransfer...
Gardado en:
| Publicado en: | BMC Infect Dis |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6626355/ https://ncbi.nlm.nih.gov/pubmed/31299917 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-019-4250-6 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|